Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-509 thorough QT and safety crossover study in healthy adults
NL-OMON37134Phase 1Active, not recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of decernotinib in rheumatoid arthritis (RA) and autoimmune disease (6 arms), sponsored by Vertex Pharmaceuticals. Primary endpoints: Safety and tolerability of multiple-dose VX-509 and Effect of VX-509 on QT/QTc interval. Started Aug 2012; status: active, not recruiting.
02
Drugs
decernotinib
03
Conditions
rheumatoid arthritis (RA)autoimmune disease
Beyond the preview
Go deeper on NL-OMON37134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37134.